Pharmaniaga Berhad delivered positive financial results for the financial year ended 31 December 2024, the group achieved a profit after zakat and taxation of RM133.8 million, marking a significant turnaround from a Loss After Zakat and Taxation of RM78.7 million in the previous year.
Pharmaniaga recorded RM3.8 billion revenue for FY2024, a 10.4% increase from RM3.4 billion in FY2023. This was predominantly driven by increased demand in the concession segment, boosted by the addition of new products to the Approved Products Purchase List (APPL), price adjustments under the new concession cycle, and expansion in the Indonesia segment, particularly with the opening of three new branches. Additionally, the RM124.9 million concession penalty reversal contributed to the improved performance.
Earnings Before Interest, Taxation, Depreciation, and Amortisation (EBITDA) grew more than twelve-fold to RM305.3 million compared to RM23.9 million in FY2023. Profit Before Zakat And Taxation (PBT) surged to RM194.2 million, rebounding from a Loss Before Zakat And Taxation (LBT) of RM78.2 million.
Meanwhile, during the quarter ended 31 December 2024 (Q4FY2024), the Group recorded RM926.4 million in revenue, a 17.3% increase from RM789.8 million in Q4FY2023. Additionally, EBITDA rebounded to RM41.3 million from a Loss Before Interest, Taxation, Depreciation, and Amortisation (LBITDA) of RM9.1 million from the corresponding quarter, demonstrating a strong recovery in the Group’s financial performance. Similarly, the quarter saw a turnaround from a LBT of RM37.4 million to a PBT of RM13.3 million.
